QS Investors’s Voyager Therapeutics VYGR Stock Holding History

QS Investors’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-14,900	Closed	-$159K	–	1260
2020 Q3	$159K	Sell	14,900 -56,400	-79%	-$662K	﹤0.01%	1094
2020 Q2	$900K	Hold	71,300	–	–	0.01%	754
2020 Q1	$653K	Buy	71,300 +300	+0.4%	+$3.44K	0.01%	779
2019 Q4	$965K	Sell	71,000 -900	-1%	-$13.1K	0.01%	787
2019 Q3	$1.24M	Buy	71,900 +100	+0.1%	+$2.1K	0.01%	715
2019 Q2	$1.96M	Buy	+71,800	New	+$1.64M	0.02%	594

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

QS Investors's VYGR Position: Q4 2020 in Review

QS Investors sold out of Voyager Therapeutics (VYGR) in Q4 2020, closing a stake of 14,900 shares — an estimated $159K sold.

QS Investors first reported a position in VYGR in Q2 2019 and held it in 6 quarters. The position peaked at $1.96M in Q2 2019. 101 funds tracked by Wall St. Rank hold VYGR as of Q4 2020.

QS Investors reported no remaining Voyager Therapeutics position as of Q4 2020 after selling out during the quarter.
QS Investors sold 14,900 Voyager Therapeutics shares in Q4 2020, an estimated $159K.
QS Investors first reported a position in Voyager Therapeutics in Q2 2019 and held it in 6 quarters.
QS Investors's Voyager Therapeutics position peaked at $1.96M in Q2 2019.
101 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2020.

Based on QS Investors's 13F filing for Q4 2020, filed 10 Feb 2021.